Jim Simons Next Cure, Inc. Transaction History
Renaissance Technologies LLC
- $63.1 Billion
- Q3 2024
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Next Cure, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 406,000 shares of NXTC stock, worth $572,460. This represents 0.0% of its overall portfolio holdings.
Number of Shares
406,000
Previous 462,144
12.15%
Holding current value
$572,460
Previous $734,000
24.25%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding NXTC
# of Institutions
49Shares Held
16.4MCall Options Held
1.4KPut Options Held
0-
Sofinnova Investments, Inc. Menlo Park, CA2.67MShares$3.77 Million0.35% of portfolio
-
Logos Global Management LP San Francisco, CA2.5MShares$3.53 Million0.37% of portfolio
-
Affinity Asset Advisors, LLC New York, NY2.3MShares$3.25 Million0.54% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.14MShares$1.61 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA987KShares$1.39 Million0.0% of portfolio
About NextCure, Inc.
- Ticker NXTC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,748,800
- Market Cap $39.1M
- Description
- NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...